U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
	Cite Document Number No. 1 Number-Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Publication Date MM-DD-YYYY		Relevant Passages or Relevant Figures Appear	
/MH/		US-7,029,858	04-18-2006	Lundgren-Akerlund	
/MH/		US-2006/0127398	6-15-2006	Lundgren-Akerlund	
/MH/ ·		US-2006/0178503	08-10-2006	Lundgren-Akerlund	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Indials	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
7MH/		WO 90/11676	10-18-1990	Centocor, Inc.		
/MH/		WO 97/14432	04-24-1997	Cor Therapeutics, Inc.		
		WO 99/51639	10.14.1000	Active Rictory AD		
/MH/		WO 03/068262	08-21-2003	Biogen, Inc.		
/MH/		WO 2004/089990	10-24-2004	Cartela AB		

	014	NON PATENT LITERATURE DOCUMENTS	Υ
Examiner Initials			Translation
/MH/		CAMPER et al., "Isolation, cloning, and sequence analysis of the integrin subunit alpha10, a beta1- associated collagen binding integrin expressed on chondrocytes," J Biol Chem., Vol. 273, pages 20383- 20389, August 7, 1998	
		CAMPER et al., "Distribution of the collagen-binding integrin alpha10beta1 during mouse development," Cell Tissue Res., Vol. 306, pages 107-116, October, 2001.	
		CHIA, "The role of adhesion molecules in atherosclerosis," Crit Rev Clin Lab Sci., Vol. 35, pages 573-602, 1998.	
		CORTI et al., "New understanding of atherosclerosis (clinically and experimentally) with evolving MRi technology in vivo," Ann NY Acad Sci., Voi. 947, pages 181-95, December, 2001.	
		DE MELKER et al., "The two phenylalanines in the GFFKR motif of the integrin alpha6A subunit are essential for heterodimerization," Biochem J., Vol. 328, pages 529-537, December, 1997.	
		DIMAYUGA et al., "Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-Induced carotid injury in apoE null mice," Biochem Biophys Res Commun., Vol. 264, pages 465-468, October 22, 1999.	
		FAYAD et al., "Clinical imaging of the high-risk or vulnerable atherosclerotic plaque," Circ Res., Vol. 89, pages 305-316, August 17, 2001.	
		FLACKE et al., "Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques," Circulation, Vol. 104, pages 1280-1285, September 11, 2001.	
		FUSTER, "Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology," Circulation, Vol. 90, pages 2126-2146, October, 1994.	
		HYNES, "Integrins: versatility, modulation, and signaling in cell adhesion," Cell, Vol. 69, pages 11-25, April 3, 1992.	
		KOZARSKY, "Gene therapy for cardiovascular disease," Curr Opin Pharmacol., Vol. 1, pages 197-201, April, 2001.	
Ψ		NAGHAVI et al., "New developments in the detection of vulnerable plaque," Curr Atheroscler Rep., Vol. 3, pages 125-135, March, 2001.	
/MH/		RAINES, "The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease," Int J Exp Pathol., Vol. 81, pages 173-182, June 2000.	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

Application Number

Filing Date

_

INFORMATION	DISCLOSURE
STATEMENT B	Y APPLICANT

(Use as many sheets as necessary)

Sheet 2 of

	NON PATENT LITERATURE DOCUMENTS		
/MH/	SKINNER et al., "Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagencoated membranes," Am J Pathol., Vol. 145, pages 1070-1081, November, 1994.		
/MH/	STARY et al., "A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association," Circulation, Vol. 92, pages 1355-1374, September 1, 1995.		
/MH/	TALTS et al., "Integrin gene targeting," Methods Mol Biol., Vol. 129, pages 153-187, 1999.		
/MH/	TANGIRALA et al., "Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice," Circulation, Vol. 100, pages 1816-1822, October 26, 1999.		
. /MH/	THYBERG et al., "Regulation of differentiated properties and proliferation of arterial smooth muscle cells," Arteriosclerosis, Vol. 10, pages 966-990, November, 1990.		
₹MH\	TSIMIKAS et al., "In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression," Arterioscler Thromb Vasc Biol., Vol. 20, pages 689-697, March, 2000.		
/MH/	YU et al., "High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent," Magn Reson Med., Vol. 44, pages 867-872, December, 2000.		
/MH/	ZHU et al., "Both apolipoprotein E and immune deficiency exacerbate neointimal hyperplasia after vascular injury in mice," Arterioscler Thromb Vasc Biol., Vol. 22, pages 450-455, March 1, 2002.		
		 ,	
· · · · · ·			
<u> </u>			

Examiner Signature	/Maher Haddad/	Date Considered	09/11/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.